본문으로 건너뛰기
← 뒤로

Axillary Nodal Positivity in Early-Stage Invasive Lobular Carcinoma: Implications for Sentinel Lymph Node Biopsy Omission.

1/5 보강
Annals of surgical oncology 📖 저널 OA 24.5% 2021: 1/6 OA 2022: 4/14 OA 2023: 6/31 OA 2024: 24/70 OA 2025: 75/257 OA 2026: 117/514 OA 2021~2026 2026
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 3/4)

유사 논문
P · Population 대상 환자/모집단
491 patients with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative, clinical T1, clinically node-negative ILC who underwent breast-conserving surgery at our institution between 2004 and 2024.
I · Intervention 중재 / 시술
breast-conserving surgery at our institution between 2004 and 2024
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
These findings indicate that omission of SLNB in ILC may carry a risk of axillary understaging with potential therapeutic implications. Pending evidence from prospective studies specifically designed for lobular histology, SLNB should continue to be considered an essential component of axillary evaluation in this subgroup.

Scardina L, D'Archi S, Accetta C, Carnassale B, Di Leone A, De Lauretis F

📝 환자 설명용 한 줄

[BACKGROUND]  Recent trials suggest omission of sentinel lymph node biopsy (SLNB) for selected early-stage breast cancer patients.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value p = 0.004

이 논문을 인용하기

↓ .bib ↓ .ris
APA Scardina L, D'Archi S, et al. (2026). Axillary Nodal Positivity in Early-Stage Invasive Lobular Carcinoma: Implications for Sentinel Lymph Node Biopsy Omission.. Annals of surgical oncology. https://doi.org/10.1245/s10434-026-19387-6
MLA Scardina L, et al.. "Axillary Nodal Positivity in Early-Stage Invasive Lobular Carcinoma: Implications for Sentinel Lymph Node Biopsy Omission.." Annals of surgical oncology, 2026.
PMID 41817936 ↗

Abstract

[BACKGROUND]  Recent trials suggest omission of sentinel lymph node biopsy (SLNB) for selected early-stage breast cancer patients. However, invasive lobular carcinoma (ILC) is underrepresented, and retrospective data indicate higher rates of nodal metastases, raising concerns about axillary understaging. This study aimed to evaluate the prevalence and predictors of nodal metastases in early-stage, clinically node-negative ILC.

[METHODS]  This study retrospectively analyzed 491 patients with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative, clinical T1, clinically node-negative ILC who underwent breast-conserving surgery at our institution between 2004 and 2024. The exclusion criteria ruled out neoadjuvant therapy, tumor larger than 2 cm, and metastatic disease at diagnosis or prior breast cancer.

[RESULTS]  Among 491 patients, 392 (79.8 %) were pN0, whereas 99 (20.2 %) had nodal metastases (pN1mi-pN3). Pathologic tumor size was significantly associated with axillary nodal involvement (p = 0.004). In contrast, histologic subtype was not significantly associated with nodal status (p = 0.15), although pleomorphic tumors demonstrated numerically higher rates of nodal involvement than classic invasive lobular carcinoma. Menopausal status was not predictive of nodal positivity (p = 0.96).

[CONCLUSIONS]  Approximately one (20.2 %) in five patients with early-stage, clinically node-negative ILC harbors occult axillary nodal metastases. Pathologic tumor size emerged as the primary determinant of nodal involvement. Pleomorphic variants showed a tendency toward higher nodal burden. These findings indicate that omission of SLNB in ILC may carry a risk of axillary understaging with potential therapeutic implications. Pending evidence from prospective studies specifically designed for lobular histology, SLNB should continue to be considered an essential component of axillary evaluation in this subgroup.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (1)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반